Israel Englander Apellis Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q4 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 71,300 shares of APLS stock, worth $1.95 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

71,300

Previous 7,800 814.1%

Holding current value

$1.95 Million

Previous $224,000 915.63%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$26.18 - $35.42 $13 Million - $17.6 Million	498,104 Added 643.66%	575,490 $18.4 Million
Q3 2024 Nov 14, 2024	SELL	$28.84 - $41.15 $3.71 Million - $5.29 Million	-128,525 Reduced 62.42%	77,386 $2.23 Million
Q2 2024 Aug 14, 2024	SELL	$38.07 - $59.71 $22.1 Million - $34.6 Million	-579,485 Reduced 73.78%	205,911 $7.9 Million
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $42.8 Million - $56 Million	772,869 Added 6169.63%	785,396 $46.2 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $33.7 Million - $58.7 Million	-906,284 Reduced 98.64%	12,527 $749,000
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $28.4 Million - $34.6 Million	370,610 Added 67.6%	918,811 $83.7 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $24.6 Million - $35.4 Million	528,565 Added 2691.82%	548,201 $36.2 Million
Q4 2022 Feb 14, 2023	SELL	$43.24 - $61.04 $10.3 Million - $14.5 Million	-238,233 Reduced 92.39%	19,636 $1.02 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $11.5 Million - $18 Million	257,869 New	257,869 $17.6 Million
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $8.92 Million - $13.6 Million	-251,497 Reduced 80.61%	60,505 $3.07 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $2.87 Million - $4.59 Million	-93,380 Reduced 23.04%	312,002 $14.8 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $7.75 Million - $17.2 Million	246,811 Added 155.65%	405,382 $13.4 Million
Q1 2021 May 17, 2021	SELL	$40.8 - $57.39 $3.39 Million - $4.77 Million	-83,143 Reduced 34.4%	158,571 $6.8 Million
Q4 2020 Feb 16, 2021	SELL	$30.79 - $57.2 $20.8 Million - $38.6 Million	-674,989 Reduced 73.63%	241,714 $13.8 Million
Q3 2020 Nov 16, 2020	SELL	$25.89 - $33.65 $4.1 Million - $5.34 Million	-158,547 Reduced 14.75%	916,703 $27.7 Million
Q2 2020 Aug 14, 2020	SELL	$24.8 - $38.49 $7 Million - $10.9 Million	-282,336 Reduced 20.8%	1,075,250 $35.1 Million
Q1 2020 May 14, 2020	BUY	$17.91 - $44.33 $13.9 Million - $34.4 Million	774,980 Added 133.02%	1,357,586 $36.4 Million
Q4 2019 Feb 14, 2020	SELL	$22.1 - $30.8 $47 Million - $65.6 Million	-2,128,655 Reduced 78.51%	582,606 $17.8 Million
Q3 2019 Nov 14, 2019	BUY	$24.09 - $32.18 $16.1 Million - $21.5 Million	667,337 Added 32.65%	2,711,261 $65.3 Million
Q2 2019 Aug 15, 2019	BUY	$18.0 - $25.34 $18.2 Million - $25.6 Million	1,010,730 Added 97.83%	2,043,924 $51.8 Million
Q2 2019 Aug 14, 2019	SELL	$18.0 - $25.34 $16.1 Million - $22.6 Million	-893,372 Reduced 46.37%	1,033,194 $14.2 Million
Q1 2019 May 14, 2019	BUY	$12.81 - $19.82 $9.53 Million - $14.7 Million	744,181 Added 62.94%	1,926,566 $37.6 Million
Q4 2018 Feb 14, 2019	BUY	$11.47 - $18.71 $863,415 - $1.41 Million	75,276 Added 6.8%	1,182,385 $15.6 Million
Q3 2018 Nov 14, 2018	BUY	$16.57 - $21.03 $3.54 Million - $4.49 Million	213,649 Added 23.91%	1,107,109 $19.7 Million
Q2 2018 Aug 14, 2018	BUY	$19.63 - $30.0 $17.5 Million - $26.8 Million	893,460 New	893,460 $19.7 Million

Others Institutions Holding APLS

# of Institutions

304

Shares Held

117M

Call Options Held

3.03M

Put Options Held

1.05M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.01B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account